Clinical trial
Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure
NCT03030222 is registered in ClinicalTrials.gov with Saint Luke's Health System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure
- Lead sponsor
- Saint Luke's Health System
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 5, 2017
- Completion date
- March 10, 2020
- Enrollment
- 65 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.